TY - JOUR
T1 - CAR-T-Cell Therapy in Multiple Myeloma
T2 - B-Cell Maturation Antigen (BCMA) and Beyond
AU - Mishra, Abhinava K.
AU - Gupta, Ashna
AU - Dagar, Gunjan
AU - Das, Dayasagar
AU - Chakraborty, Abhijit
AU - Haque, Shabirul
AU - Prasad, Chandra Prakash
AU - Singh, Archana
AU - Bhat, Ajaz A.
AU - Macha, Muzafar A.
AU - Benali, Moez
AU - Saini, Kamal S.
AU - Previs, Rebecca Ann
AU - Saini, Deepak
AU - Saha, Dwaipayan
AU - Dutta, Preyangsee
AU - Bhatnagar, Aseem Rai
AU - Darswal, Mrinalini
AU - Shankar, Abhishek
AU - Singh, Mayank
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/11
Y1 - 2023/11
N2 - Significant progress has been achieved in the realm of therapeutic interventions for multiple myeloma (MM), leading to transformative shifts in its clinical management. While conventional modalities such as surgery, radiotherapy, and chemotherapy have improved the clinical outcomes, the overarching challenge of effecting a comprehensive cure for patients afflicted with relapsed and refractory MM (RRMM) endures. Notably, adoptive cellular therapy, especially chimeric antigen receptor T-cell (CAR-T) therapy, has exhibited efficacy in patients with refractory or resistant B-cell malignancies and is now also being tested in patients with MM. Within this context, the B-cell maturation antigen (BCMA) has emerged as a promising candidate for CAR-T-cell antigen targeting in MM. Alternative targets include SLAMF7, CD38, CD19, the signaling lymphocyte activation molecule CS1, NKG2D, and CD138. Numerous clinical studies have demonstrated the clinical efficacy of these CAR-T-cell therapies, although longitudinal follow-up reveals some degree of antigenic escape. The widespread implementation of CAR-T-cell therapy is encumbered by several barriers, including antigenic evasion, uneven intratumoral infiltration in solid cancers, cytokine release syndrome, neurotoxicity, logistical implementation, and financial burden. This article provides an overview of CAR-T-cell therapy in MM and the utilization of BCMA as the target antigen, as well as an overview of other potential target moieties.
AB - Significant progress has been achieved in the realm of therapeutic interventions for multiple myeloma (MM), leading to transformative shifts in its clinical management. While conventional modalities such as surgery, radiotherapy, and chemotherapy have improved the clinical outcomes, the overarching challenge of effecting a comprehensive cure for patients afflicted with relapsed and refractory MM (RRMM) endures. Notably, adoptive cellular therapy, especially chimeric antigen receptor T-cell (CAR-T) therapy, has exhibited efficacy in patients with refractory or resistant B-cell malignancies and is now also being tested in patients with MM. Within this context, the B-cell maturation antigen (BCMA) has emerged as a promising candidate for CAR-T-cell antigen targeting in MM. Alternative targets include SLAMF7, CD38, CD19, the signaling lymphocyte activation molecule CS1, NKG2D, and CD138. Numerous clinical studies have demonstrated the clinical efficacy of these CAR-T-cell therapies, although longitudinal follow-up reveals some degree of antigenic escape. The widespread implementation of CAR-T-cell therapy is encumbered by several barriers, including antigenic evasion, uneven intratumoral infiltration in solid cancers, cytokine release syndrome, neurotoxicity, logistical implementation, and financial burden. This article provides an overview of CAR-T-cell therapy in MM and the utilization of BCMA as the target antigen, as well as an overview of other potential target moieties.
KW - B-cell maturation antigen (BCMA)
KW - CAR-T-cell therapy
KW - multiple myeloma (MM)
UR - http://www.scopus.com/inward/record.url?scp=85178106584&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85178106584&partnerID=8YFLogxK
U2 - 10.3390/vaccines11111721
DO - 10.3390/vaccines11111721
M3 - Review article
C2 - 38006053
AN - SCOPUS:85178106584
SN - 2076-393X
VL - 11
JO - Vaccines
JF - Vaccines
IS - 11
M1 - 1721
ER -